Internal Medicine

Asthma and COPD

Obstructive Airways Diseases

Amos Asamoah
October 2025
6 min read
Other Topics

Welcome to respiratory diseases, student! We're starting with two of the most common obstructive lung conditions: asthma and COPD. While both cause breathing difficulties and share some features, they're fundamentally different diseases with distinct pathophysiology, clinical courses, and management approaches. I'll guide you through understanding these differences while appreciating their similarities. Mastering these conditions is essential as they affect hundreds of millions worldwide and represent major causes of morbidity and healthcare utilization. Let's breathe deeply into this important topic!

🩺 Overview and Definitions

Asthma and COPD are both characterized by airflow limitation, but they differ in their underlying mechanisms, reversibility, and natural history.

Asthma

  • Definition: Chronic inflammatory disorder with reversible airflow obstruction
  • Key feature: Airway hyperresponsiveness
  • Pattern: Variable and fluctuating symptoms
  • Onset: Often in childhood/young adulthood

COPD

  • Definition: Persistent airflow limitation, not fully reversible
  • Key feature: Progressive, associated with inflammation
  • Pattern: Persistent and progressive symptoms
  • Onset: Usually after age 40, smoking-related
Feature Asthma COPD
Pathology Eosinophilic inflammation, bronchoconstriction Neutrophilic inflammation, parenchymal destruction
Reversibility Usually complete or significant Limited or absent
Risk Factors Atopy, family history, allergens Smoking, occupational exposures, alpha-1 antitrypsin deficiency
Clinical Course Episodic, variable Progressive, persistent
Treatment Response Excellent to bronchodilators and steroids Partial to bronchodilators, limited to steroids
Clinical Pearl: Remember the "Asthma-COPD Overlap Syndrome" (ACOS) - some patients have features of both conditions, which can make diagnosis and management challenging.

🔄 Pathophysiology

Understanding the distinct pathological processes in asthma and COPD is crucial for diagnosis and targeted treatment.

Asthma Pathophysiology

  • Type I hypersensitivity reaction
  • Mast cell activation and mediator release
  • Eosinophilic airway inflammation
  • Airway remodeling over time
  • Bronchial hyperresponsiveness

COPD Pathophysiology

  • Chronic bronchitis: mucus hypersecretion
  • Emphysema: alveolar destruction
  • Neutrophilic inflammation
  • Protease-antiprotease imbalance
  • Oxidative stress

Common Features

  • Airflow limitation
  • Airway inflammation
  • Mucus production
  • Smooth muscle hypertrophy
  • Gas exchange abnormalities
Tutor Tip: Think of asthma as "reactive airways" that overreact to triggers, while COPD is "damaged airways" from cumulative injury, primarily smoking.

👨‍⚕️ Clinical Presentation

While both conditions cause respiratory symptoms, their patterns and associated features help differentiate them.

Symptom Comparison

Symptom Asthma COPD
Cough Dry or productive, episodic Chronic, productive (especially mornings)
Wheeze Common, musical, episodic Variable, may be persistent
Dyspnea Episodic, variable, often nocturnal Progressive, persistent, exertional
Sputum Scant, if present Chronic, mucoid or purulent
Triggers Allergens, exercise, cold air, viruses Infections, pollutants, minimal triggers

Physical Examination Findings

Asthma

  • Wheezing (expiratory > inspiratory)
  • Prolonged expiratory phase
  • Hyperresonance on percussion
  • Use of accessory muscles during attacks
  • Nasal polyps, atopic dermatitis (comorbid)

COPD

  • Barrel chest (in emphysema)
  • Wheezing or diminished breath sounds
  • Pursed-lip breathing
  • Digital clubbing (if associated conditions)
  • Cachexia, muscle wasting (advanced disease)
Status Asthmaticus/COPD Exacerbation: Severe, life-threatening exacerbations unresponsive to initial bronchodilator therapy. Features include inability to speak in full sentences, diaphoresis, tachycardia, hypoxia, and altered mental status. Requires immediate hospitalization.

🔍 Diagnosis and Classification

Diagnosis relies on clinical assessment combined with pulmonary function testing, which is essential for both confirmation and severity classification.

Diagnostic Approach

Test Asthma Findings COPD Findings Key Differentiator
Spirometry Obstructive pattern, FEV1/FVC <0.7 Obstructive pattern, FEV1/FVC <0.7 Reversibility testing
Bronchodilator Response FEV1 improvement ≥12% and ≥200 mL Limited improvement (<12% or <200 mL) Key diagnostic feature
DLCO Normal or increased Decreased (especially emphysema) Helps distinguish emphysema
Chest X-ray Usually normal, hyperinflation during attacks Hyperinflation, flattened diaphragms, bullae Structural changes in COPD
Blood Tests Eosinophilia, elevated IgE Polycythemia (chronic hypoxia) Inflammatory patterns differ

Severity Classification

Asthma Severity

  • Intermittent: Symptoms ≤2 days/week
  • Mild Persistent: Symptoms >2 days/week
  • Moderate Persistent: Daily symptoms
  • Severe Persistent: Symptoms throughout day

COPD GOLD Stages

  • GOLD 1: Mild (FEV1 ≥80%)
  • GOLD 2: Moderate (FEV1 50-79%)
  • GOLD 3: Severe (FEV1 30-49%)
  • GOLD 4: Very Severe (FEV1 <30%)
Important: Never diagnose COPD without spirometry confirmation. Clinical diagnosis alone has poor accuracy, and many "COPD" patients actually have asthma or other conditions.

💊 Management Strategies

Management involves both controller medications for long-term control and reliever medications for acute symptoms, with significant differences between asthma and COPD approaches.

Pharmacological Therapy

Medication Class Asthma Role COPD Role Key Examples
Short-acting Beta Agonists (SABA) Reliever, as needed Reliever, as needed Albuterol, Levalbuterol
Inhaled Corticosteroids (ICS) First-line controller For frequent exacerbations Fluticasone, Budesonide
Long-acting Beta Agonists (LABA) Controller, with ICS First-line maintenance Salmeterol, Formoterol
Long-acting Muscarinic Antagonists (LAMA) Add-on therapy First-line maintenance Tiotropium, Umeclidinium
Leukotriene Modifiers Alternative controller Limited role Montelukast, Zafirlukast
Methylxanthines Third-line add-on Third-line add-on Theophylline
Biologics Severe, eosinophilic asthma Not indicated Omalizumab, Mepolizumab

Stepwise Treatment Approach

Asthma Steps

  • Step 1: SABA PRN
  • Step 2: Low-dose ICS
  • Step 3: Medium-dose ICS or ICS+LABA
  • Step 4: Medium/high ICS+LABA
  • Step 5: Add biologics, consider prednisone

COPD Groups

  • Group A: LAMA or LABA
  • Group B: LAMA or LABA (dyspnea-driven)
  • Group C: LAMA (exacerbation-driven)
  • Group D: LAMA+LABA, consider ICS
  • Group E: Individualized based on phenotype
Treatment Goal: For asthma, aim for total control (no symptoms, no reliever use, normal activity). For COPD, focus on symptom relief, reduced exacerbations, and improved quality of life.

⚠️ Exacerbation Management

Acute exacerbations are major events in both conditions, requiring prompt recognition and aggressive management.

Asthma Exacerbation

  • Causes: Viral infections, allergens, non-adherence
  • Treatment: SABA, systemic corticosteroids, oxygen
  • Severe cases: Ipratropium, magnesium, heliox
  • ICU indications: PCO2 >42, silent chest, exhaustion

COPD Exacerbation

  • Causes: Infections (viral/bacterial), pollution
  • Treatment: Bronchodilators, steroids, antibiotics
  • Severe cases: NIV, oxygen (carefully titrated)
  • ICU indications: Respiratory acidosis, altered mental status
Clinical Insight: In COPD exacerbations, be cautious with oxygen therapy - aim for SpO2 88-92% to avoid suppressing respiratory drive and worsening hypercapnia.

🌱 Non-Pharmacological Management

Comprehensive management extends beyond medications to address the whole patient and their environment.

Lifestyle Interventions

  • Smoking cessation (critical for both)
  • Allergen avoidance (asthma)
  • Pulmonary rehabilitation (COPD)
  • Vaccinations (influenza, pneumococcal)

Monitoring & Education

  • Peak flow monitoring (asthma)
  • Action plans for exacerbations
  • Proper inhaler technique education
  • Nutritional support (COPD cachexia)

Advanced Therapies

  • Bronchial thermoplasty (severe asthma)
  • Lung volume reduction surgery (emphysema)
  • Lung transplantation (end-stage)
  • Long-term oxygen therapy (COPD with hypoxia)
Pro Tip: Always check inhaler technique - up to 90% of patients use inhalers incorrectly, which significantly reduces treatment effectiveness.

🧠 Key Takeaways

  • Asthma is reversible airway obstruction with inflammation, while COPD is progressive and not fully reversible
  • Asthma typically begins earlier in life, COPD after age 40 with smoking history
  • Spirometry with bronchodilator response is essential for diagnosis and differentiation
  • ICS are first-line for asthma, while LAMA/LABA are first-line for COPD
  • Both require reliever medications for acute symptoms
  • Exacerbation management differs in oxygen targets and specific therapies
  • Non-pharmacological approaches are crucial components of comprehensive care
  • Patient education and proper inhaler technique dramatically impact outcomes

🧭 Conclusion

We've explored the intricate world of obstructive airways diseases, student—understanding both the shared features and crucial differences between asthma and COPD. Remember that while both cause breathing difficulties, their underlying mechanisms, natural history, and treatment approaches differ significantly. I encourage you to master spirometry interpretation and bronchodilator testing, as these are essential for accurate diagnosis. Excellent work building your respiratory knowledge! Next, we'll examine pneumonia and its various presentations.

In obstructive lung diseases, the goal isn't just to treat the disease but to empower patients to manage their condition and maintain quality of life.

← Previous Topic: Arrhythmias Next Topic: Pneumonia →